ID Week

Whether the oft-repeated pattern of initial drug success followed by increasing resistance plays out in the future for many drugs remains to be seen.

David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.

About 500,000 Americans fall ill from Clostridium difficile infections every year.

Dr. Maria Bye, an epidemiologist at the Minnesota Department of Health shares some unsettling news when it comes to C. difficile: dentists’ prescribing habits may be contributing to CDI incidence.

David Huang, PhD, MD, shares the recent results of the REVIVE-2 trial.

Candidemia is the most common healthcare-associated bloodstream infection in the United States, with an incidence of 5-15 per 100,000 persons.

Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

It is only a matter of time before the next infectious disease pandemic hits and healthcare officials need to be prepared.

Dr. Monique Foster, CDC, and Dr. Eric McDonald, San Diego County Health and Human Services Agency, discuss the surprising return of hepatitis A virus as part of the Late Breakers I symposium.

James S. Lewis, PharmD, FIDSA, addresses the issues that surround current antibiotic development.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains how her future research aims to understand the effects of ceftazidime-avibactam in different patient populations.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses the significance of the findings of her research on Ceftazidime-Avibactam.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her findings regarding patients treated with ceftazidime-avibactam for carbapenem-resistant Enterobacteriaceae infections and carbapenem-resistant Pseudomonas infections.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her research on the efficacy of ceftazidime-avibactam against infections caused by gram-negative organisms.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains how his research can assess clinical well-being of patients with skin and soft tissue infections.

Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses potential strategies to reduce incidence of acute kidney injuries due to vancomycin and pip/tazo combination therapy.

Oluwatoyin (Toyin) Adeyemi, MD, attending physician of infectious diseases, at Cook County Health and Hospital System, discusses the next steps in implementing activities for the CORE Healthy Aging Initiative.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, discusses the clinical significance of the results of his study on readmission rates among patients with skin and soft tissue infections.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), discusses the CDC’s HCV universal birth cohort testing program.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains that resources for skin and soft tissue infections need to be directed at emergency departments.

Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses alternative therapies to the acute kidney injury-causing combination of vancomycin piperacillin/tazobactam.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains that hepatitis C infection awareness has been on the rise in the United States.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains why it’s important to understand the prevalence of skin and soft tissue infections.

Oluwatoyin (Toyin) Adeyemi, MD, attending physician of infectious diseases, at Cook County Health and Hospital System, discusses the CORE Healthy Aging Initiative (CHAI).

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, discusses the importance of new medications to treat hepatitis C.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, discusses the biggest challenges associated with classifying and treating skin and soft tissue infections.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains why it’s important for individuals to know that they are infected with hepatitis C, although they may be asymptomatic.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, discusses which skin and soft tissue infections (SSTIs) are likely to be drug-resistant.